BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 17561711)

  • 1. Lactate dehydrogenase is a prognostic indicator for prostate cancer patients with bone metastasis.
    Naruse K; Yamada Y; Aoki S; Taki T; Nakamura K; Tobiume M; Zennami K; Katsuda R; Sai S; Nishio Y; Inoue Y; Noguchi H; Hondai N
    Hinyokika Kiyo; 2007 May; 53(5):287-92. PubMed ID: 17561711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
    Saito T; Hara N; Kitamura Y; Komatsubara S
    Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum interleukin 6 as a prognostic factor in patients with prostate cancer.
    Nakashima J; Tachibana M; Horiguchi Y; Oya M; Ohigashi T; Asakura H; Murai M
    Clin Cancer Res; 2000 Jul; 6(7):2702-6. PubMed ID: 10914713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lactate dehydrogenase, Gleason score and HER-2 overexpression are significant prognostic factors for M1b prostate cancer.
    Yamada Y; Nakamura K; Aoki S; Tobiume M; Zennami K; Kato Y; Nishikawa G; Yoshizawa T; Itoh Y; Nakaoka A; Yoshida E; Uchiyama T; Honda N
    Oncol Rep; 2011 Apr; 25(4):937-44. PubMed ID: 21249322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
    Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
    Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical studies on the prognostic factors in prostate cancer].
    Horii Y; Yoshida T; Hirai S; Yamauchi T
    Hinyokika Kiyo; 1998 Oct; 44(10):701-5. PubMed ID: 9850833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases.
    Petrioli R; Rossi S; Caniggia M; Pozzessere D; Messinese S; Sabatino M; Marsili S; Correale P; Salvestrini F; Manganelli A; Francini G
    Urology; 2004 Feb; 63(2):321-6. PubMed ID: 14972482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of global grading system of Gleason score in patients with prostate cancer with bone metastasis.
    Kambara T; Oyama T; Segawa A; Fukabori Y; Yoshida K
    BJU Int; 2010 Jun; 105(11):1519-25. PubMed ID: 19912185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
    Xie W; Nakabayashi M; Regan MM; Oh WK
    Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
    Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
    Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors in metastatic prostate cancer.
    Yigitbasi O; Ozturk U; Goktug HN; Gucuk A; Bakirtas H
    Urol Oncol; 2011; 29(2):162-5. PubMed ID: 19450995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
    J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors in patients with metastatic (stage D2) prostate cancer: experience from the Scandinavian Prostatic Cancer Group Study-2.
    Jørgensen T; Kanagasingam Y; Kaalhus O; Tveter KJ; Bryne M; Skjørten F; Berner A; Danielsen HE
    J Urol; 1997 Jul; 158(1):164-70. PubMed ID: 9186346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer.
    Burdick MJ; Reddy CA; Ulchaker J; Angermeier K; Altman A; Chehade N; Mahadevan A; Kupelian PA; Klein EA; Ciezki JP
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1439-45. PubMed ID: 18963536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serum osteoprotegerin as a novel marker of bone metastasis in prostate cancer].
    Chen HX; Li HZ; Li HJ; Shi BB; Jin W; Cheng XQ
    Zhonghua Wai Ke Za Zhi; 2007 Mar; 45(6):412-4. PubMed ID: 17537330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of alpha1-antichymotrypsin-PSA complex for predicting bone metastases of prostate cancer.
    Kikuchi E; Nakashima J; Ishibashi M; Ohigashi T; Oya M; Nakagawa K; Miyajima A; Murai M
    Urology; 2006 Aug; 68(2):371-5. PubMed ID: 16904455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy.
    Stone NN; Potters L; Davis BJ; Ciezki JP; Zelefsky MJ; Roach M; Shinohara K; Fearn PA; Kattan MW; Stock RG
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):341-6. PubMed ID: 18597953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE.
    Ryan CJ; Elkin EP; Cowan J; Carroll PR
    Cancer; 2007 Jul; 110(1):81-6. PubMed ID: 17516446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.